163 related articles for article (PubMed ID: 24808634)
1. Circulating biomarkers of immune activation distinguish viral suppression from nonsuppression in HAART-treated patients with advanced HIV-1 subtype C infection.
Malherbe G; Steel HC; Cassol S; de Oliveira T; Seebregts CJ; Anderson R; Cassol E; Rossouw TM
Mediators Inflamm; 2014; 2014():198413. PubMed ID: 24808634
[TBL] [Abstract][Full Text] [Related]
2. Systemic Immune Activation Profiles of HIV-1 Subtype C-Infected Children and Their Mothers.
Makhubele TG; Steel HC; Anderson R; van Dyk G; Theron AJ; Rossouw TM
Mediators Inflamm; 2016; 2016():9026573. PubMed ID: 27019552
[TBL] [Abstract][Full Text] [Related]
3. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy.
Kamat A; Misra V; Cassol E; Ancuta P; Yan Z; Li C; Morgello S; Gabuzda D
PLoS One; 2012; 7(2):e30881. PubMed ID: 22363505
[TBL] [Abstract][Full Text] [Related]
4. Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy.
Hattab S; Guiguet M; Carcelain G; Fourati S; Guihot A; Autran B; Caby F; Marcelin AG; Costagliola D; Katlama C
HIV Med; 2015 Oct; 16(9):553-62. PubMed ID: 25944318
[TBL] [Abstract][Full Text] [Related]
5. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation.
Wada NI; Jacobson LP; Margolick JB; Breen EC; Macatangay B; Penugonda S; Martínez-Maza O; Bream JH
AIDS; 2015 Feb; 29(4):463-71. PubMed ID: 25630041
[TBL] [Abstract][Full Text] [Related]
6. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women.
Keating SM; Golub ET; Nowicki M; Young M; Anastos K; Crystal H; Cohen MH; Zhang J; Greenblatt RM; Desai S; Wu S; Landay AL; Gange SJ; Norris PJ;
AIDS; 2011 Sep; 25(15):1823-32. PubMed ID: 21572306
[TBL] [Abstract][Full Text] [Related]
7. The effect of a year of highly active antiretroviral therapy on immune reconstruction and cytokines in HIV/AIDS patients.
Yao Y; Luo Y; He Y; Zheng Y; Zhang Q; Zhou H; Zeng S; Chen Z; He B; He M
AIDS Res Hum Retroviruses; 2013 Apr; 29(4):691-7. PubMed ID: 23151174
[TBL] [Abstract][Full Text] [Related]
8. Dysregulated Immune Activation in Second-Line HAART HIV+ Patients Is Similar to That of Untreated Patients.
Espíndola MS; Lima LJ; Soares LS; Cacemiro MC; Zambuzi FA; de Souza Gomes M; Amaral LR; Bollela VR; Martins-Filho OA; Frantz FG
PLoS One; 2015; 10(12):e0145261. PubMed ID: 26684789
[TBL] [Abstract][Full Text] [Related]
9. High CXCL10/IP-10 levels are a hallmark in the clinical evolution of the HIV infection.
Valverde-Villegas JM; de Medeiros RM; Ellwanger JH; Santos BR; Melo MG; Almeida SEM; Chies JAB
Infect Genet Evol; 2018 Jan; 57():51-58. PubMed ID: 29122683
[TBL] [Abstract][Full Text] [Related]
10. Short communication: decreasing soluble CD30 and increasing IFN-gamma plasma levels are indicators of effective highly active antiretroviral therapy.
Sadeghi M; Süsal C; Daniel V; Naujokat C; Zimmermann R; Huth-Kühne A; Opelz G
AIDS Res Hum Retroviruses; 2007 Jul; 23(7):886-90. PubMed ID: 17678471
[TBL] [Abstract][Full Text] [Related]
11. A Low Frequency of IL-17-Producing CD8
Perdomo-Celis F; Feria MG; Taborda NA; Rugeles MT
Front Immunol; 2018; 9():2502. PubMed ID: 30420859
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy.
Ostrowski SR; Katzenstein TL; Pedersen M; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2006 Jun; 63(6):478-86. PubMed ID: 16764702
[TBL] [Abstract][Full Text] [Related]
13. The combination of CXCL9, CXCL10 and CXCL11 levels during primary HIV infection predicts HIV disease progression.
Yin X; Wang Z; Wu T; Ma M; Zhang Z; Chu Z; Hu Q; Ding H; Han X; Xu J; Shang H; Jiang Y
J Transl Med; 2019 Dec; 17(1):417. PubMed ID: 31836011
[TBL] [Abstract][Full Text] [Related]
14. Elevated plasma soluble CD14 and skewed CD16+ monocyte distribution persist despite normalisation of soluble CD163 and CXCL10 by effective HIV therapy: a changing paradigm for routine HIV laboratory monitoring?
Castley A; Berry C; French M; Fernandez S; Krueger R; Nolan D
PLoS One; 2014; 9(12):e115226. PubMed ID: 25544986
[TBL] [Abstract][Full Text] [Related]
15. The suppression of immune activation during enfuvirtide-based salvage therapy is associated with reduced CCR5 expression and decreased concentrations of circulating interleukin-12 and IP-10 during 48 weeks of longitudinal follow-up.
Carsenti-Dellamonica H; Saïdi H; Ticchioni M; Guillouet de Salvador F; Dufayard Cottalorda J; Garraffo R; Dellamonica P; Durant J; Gougeon ML
HIV Med; 2011 Feb; 12(2):65-77. PubMed ID: 20500532
[TBL] [Abstract][Full Text] [Related]
16. Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.
Hattab S; Guihot A; Guiguet M; Fourati S; Carcelain G; Caby F; Marcelin AG; Autran B; Costagliola D; Katlama C
BMC Infect Dis; 2014 Mar; 14():122. PubMed ID: 24589015
[TBL] [Abstract][Full Text] [Related]
17. IMMUNOLOGICAL PROFILES IN HIV POSITIVE PATIENTS FOLLOWING HAART INITIATION IN KIGALI, RWANDA.
Twizerimana AP; Mwatha J; Musabyimana JP; Kayigi E; Harelimana Jde D; Karanja SM; Mutesa L
East Afr Med J; 2014 Aug; 91(8):261-6. PubMed ID: 26862650
[TBL] [Abstract][Full Text] [Related]
18. The effects of highly active antiretroviral therapy on the serum levels of pro-inflammatory and anti-inflammatory cytokines in HIV infected subjects.
Osuji FN; Onyenekwe CC; Ahaneku JE; Ukibe NR
J Biomed Sci; 2018 Dec; 25(1):88. PubMed ID: 30501642
[TBL] [Abstract][Full Text] [Related]
19. Plasma Biomarkers of Human Immunodeficiency Virus-Related Systemic Inflammation and Immune Activation in Sub-Saharan Africa Before and During Suppressive Antiretroviral Therapy.
Kroeze S; Wit FW; Rossouw TM; Steel HC; Kityo CM; Siwale M; Akanmu S; Mandaliya K; de Jager M; Ondoa P; Reiss P; Rinke de Wit TF; Kootstra N; Hamers RL
J Infect Dis; 2019 Aug; 220(6):1029-1033. PubMed ID: 31086991
[TBL] [Abstract][Full Text] [Related]
20. Plasma CXCL10, sCD163 and sCD14 Levels Have Distinct Associations with Antiretroviral Treatment and Cardiovascular Disease Risk Factors.
Castley A; Williams L; James I; Guelfi G; Berry C; Nolan D
PLoS One; 2016; 11(6):e0158169. PubMed ID: 27355513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
